Arrhythmia in Hemodialysis Patients
Key facts
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Where
- Canada2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 18 people enrolled
- Started
- 17 Oct 2019
- Ended
- 24 Jun 2026
- Type of study
- Interventional
- Treatments tested
- Reveal LINQ insertable cardiac monitoring system
- Record updated
- 26 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- No significant residual renal function (<250ml of urine per day)
- Must be on hemodialysis for at least 3 months
- Age ≥18 years
- Able/willing to provide informed consent
Who cannot take part
- Prior diagnosis of chronic arrhythmia and/or are on anti-arrhythmic drugs
- Presence of a pacemaker and implantable cardioverter defibrillator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients receiving dialysis for kidney failure suffer from very high rates of sudden cardiac death due to abnormal heart rhythms and perfusion defects associated with HD treatment. It has previously been recognized that patients suffer heart injury during the dialysis procedure which may be an important factor for investigation. The study uses a simple implantable device that can monitor heart rhythms over time to gather information on the type of abnormal rhythms that occur in dialysis patients. This information will be combined with ultrasound and x-ray scans of the heart that will also be collected. The goal is to understand the relationship between the abnormal rhythms and injury to the heart during dialysis and what causes these injuries. The information gathered in this study will be used to compare the accuracy of an in house personalized computational model to predict potential cardiac injuries when patients undergo HD treatment.
The group in the trial
- Reveal LINQ insertable cardiac monitoring systemTreatment being tested
In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigation of Electrophysiological Substrate of Arrhythmia in Hemodialysis Patients
- Record updated
- 26 June 2026